Xeris Biopharma Holdings, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plan
The following table describes for the three months ended September 30, 2025 each trading arrangement under which the Company’s directors or officers adopted, materially modified, or terminated any contract, instruction, or written plan for the purchase or sale of Company securities under a “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
| Name & Title · Date Adopted · Type of Trading Arrangement(1) · Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement · Expiration Date(2) | |||||
|---|---|---|---|---|---|
| Beth HechtChief Legal Officer and Corporate Secretary | 8/8/2025 | Rule 10b5-1 | 200,000 | 10/31/2026 | |
| John JohnsonMember of Board of Directors | 8/13/2025 | Rule 10b5-1 | 25,367 | (3) | 6/12/2026 |
| John ShannonChief Executive Officer and Director | 8/14/2025 | Rule 10b5-1 | 48,149 | (4) | 8/14/2026 |
| Steve PieperChief Financial Officer | 8/18/2025 | Rule 10b5-1 | 70,000 | 12/31/2026 | |
| Dawn HalkuffMember of Board of Directors | 9/4/2025 | Rule 10b5-1 | 20,000 | 6/12/2026 | |
| Kevin McCullochPresident and Chief Operating Officer | 9/4/2025 | Rule 10b5-1 | 230,000 | 12/31/2026 | |
| BJ BormannMember of Board of Directors | 9/12/2025 | Rule 10b5-1 | 31,000 | 12/31/2026 | |
(1)Each trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).
(2)Each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales and (b) the date listed in the table. Each trading arrangement marked as a “Rule 10b5-1 Trading Arrangement” only permits transactions upon expiration of the applicable mandatory cooling-off period under the Rule.
(3)Includes shares underlying stock options expiring in October 2025.
(4)Includes shares underlying stock option expiring in February 2027.
During the quarter ended September 30, 2025, no other directors or officers adopted, materially modified, orterminated any contract, instruction, or written plan for the purchase or sale of Company securities under a “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement.”
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.